Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Midlab Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and 2 distinct art units. This one-to-one ratio between the 2 pending office actions and the 2 distinct examiners indicates that the company's current biotechnology filings are being reviewed in isolation from one another.
The busiest examiner, MEYERS, ELIZABETH ANNE, is handling 1 pending action. With 2 pending office actions in 2 distinct art units, the company must address the specific biotechnology standards of two separate examination groups. This distribution involves 2 distinct examiners, requiring the company to tailor its arguments to two different sets of preferences. Because there is no overlap in personnel or art units, the prosecution strategy must be independently managed for each of the 2 pending office actions in the pharmaceutical space.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MEYERS, ELIZABETH ANNE | 1 | 22.2% | +93.3% |
| GEBREMICHAEL, BRUK A | 1 | 22.0% | +23.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16256585 | COMPLIANCE SYSTEM FOR USE WITH JANITORIAL AND CLEANING PRODUCTS | GEBREMICHAEL, BRUK A | 55d |
| 19032773 | ANTIMICROBIAL COMPOSITION | MEYERS, ELIZABETH ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16256585 | COMPLIANCE SYSTEM FOR USE WITH JANITORIAL AND CLEANING PRODUCTS | GEBREMICHAEL, BRUK A | 55d |
| 19032773 | ANTIMICROBIAL COMPOSITION | MEYERS, ELIZABETH ANNE | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| 3715 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19032773 | ANTIMICROBIAL COMPOSITION | MEYERS, ELIZABETH ANNE | 1617 | §103§112 | Non-Final OA | — | Pending | Jan 21, 2025 |
| 16256585 | COMPLIANCE SYSTEM FOR USE WITH JANITORIAL AND CLEANING PRODUCTS | GEBREMICHAEL, BRUK A | 3715 | §103 | Final Rejection | 55d | Pending | Jan 24, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMidlab Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Elizabeth Anne Meyers has the most, with 1 of Midlab Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
